皮肤性病诊疗学杂志2024，Vol.31Issue(1)：15-21,7.DOI:10.3969/j.issn.1674-8468.2024.01.003
SCN9A基因突变引起原发性红斑肢痛症1例及文献复习
Primary erythromelalgia caused by SCN9A gene mutation:A case report and literature review
孙翠翠 1杨赛 2郑航 1梁云生 2林志淼 2陈永锋1
作者信息
- 1. 安徽医科大学广东皮肤病临床学院||南方医科大学皮肤病医院,广东 广州 510091
- 2. 南方医科大学皮肤病医院,广东 广州 510091
- 折叠
摘要
Abstract
Objective To report a case of hereditary skin disease mainly characterized by burning pain of the lower legs and feet,accompanied by flush and elevated skin temperature,and to identify the pathogenic genes and mutation sites in order to explore effective treatment methods.Methods The clinical data of the case were collected and peripheral blood was taken from the patient and relatives to extract genomic DNA.Next-generation sequencing of hereditary skin dis-ease genes was performed,and suspected pathogenic mutations were verified with Sanger sequen-cing.The patient was treated with aspirin for anti-inflammation,rizatriptan benzoate tablet,mexil-etine hydrochloride,carbamazepine,local injection of botulinum toxin analgesia,topical com-pound polymyxin B ointment and cooling therapy.Results A heterozygous mutation of SCN9A:NM_002977.3:c.688+142G＞A or SCN9A:ENST00000375387.4:c.626G＞A was detected in the patient's peripheral blood genomic DNA.The same mutation was found in the patient's sister,an uncle and a cousin.Based on the pathogenic gene and clinical manifestations,the patient was diagnosed with primary erythromelalgia(PEM).After the treatment,the pain was significantly al-leviated.Conclusions The intron mutation of NM_002977.3:c.688+142G＞A or missense mu-tation c.626G＞A(p.Gly209Asp)of the SCN9A gene is the cause of PEM in this case.Combina-tion therapy of aspirin,rizatriptan benzoate,mexiletine hydrochloride,carbamazepine and local treatment can effectively control the symptoms of PEM,reduce the frequency of acute attacks and improve the prognosis.关键词
原发性红斑肢痛症/SCN9A基因/Nav1.7通道Key words
erythromelalgia/SCN9A gene/Nav1.7 channel引用本文复制引用
孙翠翠,杨赛,郑航,梁云生,林志淼,陈永锋..SCN9A基因突变引起原发性红斑肢痛症1例及文献复习[J].皮肤性病诊疗学杂志,2024,31(1):15-21,7.
